secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cabaletta Bio, Inc. (CABA)
CIK:        0001759138
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0000950170-25-104570
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cabaletta Bio Q2 2025 R&D expenses $37.6M, cash $194.7M; myositis registrational cohort on track for 2H25
--------------------------------------------------------------------------------

- R&D expenses $37.6M (vs $23.4M in Q2 2024); G&A $8.3M (vs $6.9M).
- Cash, cash equivalents & short-term investments $194.7M as of June 30, 2025; runway into 2H26.
- Closed $100M public offering (net ~$94M) in June 2025 to support rese-cel development and commercial readiness.
- Myositis registrational cohort enrollment on track for 2H25; first BLA submission for rese-cel anticipated in 2027.
- FDA meetings planned for lupus (3Q25), scleroderma (4Q25), and myasthenia gravis (1H26) registrational designs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759138/000095017025104570/0000950170-25-104570-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759138/000095017025104570/caba-20250807.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-104570

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer